Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423379 · ClinicalTrials.gov registry record
XIENCE Skypoint Large Vessel Post Approval Study
A clinical trial of Coronary Artery Disease, sponsored by Abbott Medical Devices.
- Active
- Registry status
- 102
- Enrollment target
- 18
- Study locations
NCT05423379: Active study of Coronary Artery Disease, sponsored by Abbott Medical Devices.
NCT05423379 is a study of Coronary Artery Disease that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 102 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423379, a study of Coronary Artery Disease, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 18
- Study locations
Study Summary
SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during commercial use in a real-world setting.
Primary Outcome
TLF is defined as the composite of cardiac death, myocardial infarction related to the target vessel (TV-MI), or ischemic driven target lesion revascularization (ID-TLR).
Conditions Studied
Interventions
- DEVICE XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)
Study Locations (18)
Texas
- Hendrick Medical Center - Abilene
- Austin Heart - Austin
- The Heart Hospital Baylor Plano - Plano
- Shannon Clinic - San Angelo
Florida
- Memorial Hospital Jacksonville - Jacksonville
- Tallahassee Research Institute - Tallahassee
South Carolina
- Anmed Health - Anderson
- Greenville Health System - Greenville
Other
- Hospital Universitario Marqués de Valdecilla - Santander
- Hospital Virgen de Rocio - Seville
Arkansas
- Arkansas Heart Hospital - Little Rock
Kansas
- Via Christi Regional Medical Center - St. Francis Campus - Wichita
Nebraska
- Bryan Heart - Lincoln
New York
- Lenox Hill Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2027-08-30 |
What the registry record for NCT05423379 still lists
NCT05423379 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) is the first listed.
NCT05423379 lists 18 locations in 12 states (Texas, Florida, South Carolina).
Frequently Asked Questions
What is clinical trial NCT05423379 about?
NCT05423379 is a clinical study titled "XIENCE Skypoint Large Vessel Post Approval Study". SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during ...
What is the current status of trial NCT05423379?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2022-09-14. Estimated completion is 2027-08-30.
What conditions does trial NCT05423379 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT05423379?
The interventions under investigation include: XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) (DEVICE).
Who is sponsoring clinical trial NCT05423379?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05423379 being conducted?
This trial has 18 study locations across Arkansas, Florida, Kansas, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05423379's enrollment target sits among peer trials
102 147th of 219 higher than 71 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI